Abstract:Aim: To perform a comparative analysis of the efficacy of antihypertensive therapy (AHT) containing spironolactone or eplerenone in patients with essential arterial hypertension (AH) and atrial fibrillation (AF). Material and methods: The study included 99 male and female patients with essential AH complicated by permanent AF, who were receiving the outpatient treatment at the National Specialized Scientific and Practical Medical Center of Cardiology (Tashkent). The patients aged 61.3±9.5 years, the mean duration of AH was 12.9±8.3 years. All patients were divided into two groups: Group 1, patients who completed a 6-month combination AHT containing spironolactone (n=51); Group 2, patients who completed a 6-month combination AHT containing eplerenone (n=48). AF was diagnosed by electrocardiogram (ECG) and/or 24-hour ECG monitoring according to standard diagnostic criteria. The ECG study was performed in compliance with the American Society of Echocardiography Guidelines in M- and B-modes. The degree of structural vascular alterations was determined by the intima-media thickness of the common carotid artery by duplex scanning and microalbuminuria in morning urine. The concentrations of sex hormones were measured by the enzyme immunoassay. The serum concentrations of lipids, glucose, creatinine, and uric acid were measured by the enzymatic method. The glomerular filtration rate (GFR) was calculated with the EPI formula. Results of all studies were considered statistically significant at p<0.05. Results: The proportion of patients who achieved the target diastolic blood pressure (BP) values was significantly greater in the eplerenone-containing treatment group than in the spironolactone-containing treatment group: 87.8% vs. 67.5% (p=0.043). The proportion of patients who simultaneously achieved the target systolic and diastolic BP values was slightly greater in the eplerenone-containing treatment group than in the spironolactone-containing group (100% vs. 92.1%, p=0.060). The best cardioprotective efficacy was observed in the group of combination AHT containing eplerenone. Specifically, in Group 2, the left ventricular ejection fraction (LVEF) was significantly improved compared to Group 1: from 55.4±10.6% at baseline to 52.6±9.1% in Group 1 (p>0.05) and from 54.8±8.8% at baseline to 58.2±6.4% in Group 2 (p<0.02). Only in Group 2, the left atrial volume index (LAVI) was significantly decreased compared to Group 1. Thus, in Group 1, the LAVI changed from 42.2±15.1 ml/m2 at baseline to 40.4±12.2 ml/m2 (p>0.05) and in Group 2, from 41.2±15.3 ml/m2 at baseline to 37.3±13.5 ml/m2 after the treatment (p<0.05); the ∆% LAVI in the eplerenone group was -5.9% vs. -0.36% in the spironolactone group. In men of Group 1, estradiol significantly increased from 13.9±12.6 pmol/l at baseline to 22.7±12.4 pmol/l (p<0.001). Conclusion: The good antihypertensive efficacy of the 6-month combination therapy containing eplerenone was significantly superior to spironolactone in achieving the target BP values. The eplerenone-containing treatment significantly improved LVEF and decreased LAVI compared to the spironolactone-containing treatment. A trend towards a beneficial effect of the AHT containing eplerenone on concentrations of sex hormones was noted in both women and men.

Effect of Aldosterone Receptor Antagonist on the Treatment of Patients with Dilated Cardiomyopathy

The Influence of Aldosterone Antagonists on Left Ventricular Diastolic Function of the Patients with Coronary Heart Disease

Effect of statin on improves cardiac diastolic function and reduces exercise B-type natriuretic peptide level

Effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension

The effect of spironolactone on some neurohormonal factors in patients suffering cardiac insufficiency secon-dary to dilated cardiomyopathy

Effect of spironolactone on cardiac remodeling after acute myocardial infarction

Effect of amlodipine on tumor necrosis factor-α, interleukin-1 and interleukin-6 in patients with heart failure

Effect of Spironolactone on Some Neurohormonal Factors in Elderly Patients Suffering Cardiac Insufficiency Secondary to Hypertension

The effects of Spironolactone on vascular endothelium function in patients with CHF

Effects of Valsartan And/or Spironolactone on Myocardial Remodeling in the Spontaneous Hypertensive Rats

The effect of different treatment strategies on glycolipid metabolism disorders and cardiovascular events in primary aldosteronism

Low Dose Spironolactone Alleviates Cardiac Remolding in Patients with NYHA Daass Ⅰ - Ⅱ Heart Failure

Eeffect of Spironolactone on Ventricular Remodeling in Patients with Asymptomatic Left Ventricular Systolic Dysfunction

Impact of Mineralocorticoid Receptor Antagonists on Changes in Cardiac Structure and Function of Left Ventricular Dysfunction

Effect of Atorvastatin on Myocardial Fibrosis Induced by Aldosterone

A Prospective Comparative Study on Cardiac Alterations after Surgery and Drug Treatment of Primary Aldosteronism.

Comparative Analysis of The Effectiveness of Antihypertensive Therapy Including Spironolactone and Eplerenone in Patients With Essential Hypertension and Atrial Fibrillation

Retrospective study on the short-term efficacy of different doses of Spironolactone in patients with heart failure of ischemic cardiomyopath and the influence of ventricular remodeling markers

Tolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism

Efficacy and safety of spironolactone in systolic heart failure patients with mild renal dysfunction

Cardiac Structural Changes in Idiopathic Hyperaldosteronism and Treatment with Spironolactone